

Resource Summary Report

Generated by ASWG on Aug 15, 2026

Brilliant Violet 421(TM) anti-human CD34

RRID:AB_2561358

Type: Antibody

Proper Citation

BioLegend Cat# 343610, RRID:AB_2561358

Antibody Information

URL: http://antibodyregistry.org/AB_2561358

Proper Citation: BioLegend Cat# 343610, RRID:AB_2561358

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD34

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: Clone 561

Antibody ID: AB_2561358

Vendor: BioLegend

Catalog Number: 343610

Alternative Catalog Numbers: 343609

Record Creation Time: 20250819T214910+0000

Record Last Update: 20250820T001153+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD34.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD34.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

He S, et al. (2025) Systemic immune activity occurs during human immune system maturation. *Cell*, 188(25), 7291.

Gao M, et al. (2025) SUCLG1 deficiency-induced histone succinylation impairs oncogene expression in acute myeloid leukemia. *Cell reports*, 44(8), 116147.

Pham J, et al. (2025) Space-associated stem cell hallmarks of aging and resilience in astronauts. *Cell stem cell*, 32(12), 1886.

Sahu SU, et al. (2025) Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells. *Nature protocols*.

Derks LLM, et al. (2025) Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early-life DNMT3A mutations. *HemaSphere*, 9(12), e70262.

Sahu S, et al. (2024) Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells. *bioRxiv : the preprint server for biology*.

Middelkamp S, et al. (2023) Comprehensive single-cell genome analysis at nucleotide resolution using the PTA Analysis Toolbox. *Cell genomics*, 3(9), 100389.

Martin-Rufino JD, et al. (2023) Massively parallel base editing to map variant effects in human hematopoiesis. *Cell*, 186(11), 2456.

Hasaart KAL, et al. (2022) Human induced pluripotent stem cells display a similar mutation burden as embryonic pluripotent cells in vivo. *iScience*, 25(2), 103736.

de Kanter JK, et al. (2021) Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients. *Cell stem cell*, 28(10), 1726.

Tong J, et al. (2021) Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. *Cell stem cell*, 28(3), 502.

Tong J, et al. (2021) Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms. *Cell stem cell*, 28(4), 780.

Nagpal N, et al. (2020) Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. *Cell stem cell*, 26(6), 896.

Dinh HQ, et al. (2020) Coexpression of CD71 and CD117 Identifies an Early Unipotent Neutrophil Progenitor Population in Human Bone Marrow. *Immunity*, 53(2), 319.

Evans WS, et al. (2020) Sitting decreases endothelial microparticles but not circulating angiogenic cells irrespective of lower leg exercises: a randomized cross-over trial. *Experimental physiology*, 105(8), 1408.

Hess DA, et al. (2020) Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. *Cell reports. Medicine*, 1(2), 100018.

Seo GY, et al. (2018) LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection. *Cell host & microbe*, 24(2), 249.